We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+4.37%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$338M
AUM Growth
-$1.49B
Cap. Flow
+$44.3M
Cap. Flow %
13.09%
Top 10 Hldgs %
50.11%
Holding
82
New
26
Increased
20
Reduced
13
Closed
22

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$21.3M
2
IART icon
Integra LifeSciences
IART
+$13.4M
3
ABBV icon
AbbVie
ABBV
+$12.8M
4
AHCO icon
AdaptHealth
AHCO
+$9.39M
5
EHC icon
Encompass Health
EHC
+$8.7M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$6.95M
2
ICUI icon
ICU Medical
ICUI
+$6.55M
3
LH icon
Labcorp
LH
+$6.3M
4
CNC icon
Centene
CNC
+$5.94M
5
SIBN icon
SI-BONE Inc
SIBN
+$5.57M

Sector Composition

Rank Sector Weight
1 Healthcare 85.42%
2 Miscellaneous 14.58%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$795B
$30.8M 9.1%
91,300
+13,700
+18% +$4.54M
BMY icon
2
Bristol-Myers Squibb
BMY
$130B
$23.5M 6.96%
390,156
+354,047
+980% +$21.3M
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$20.5M 6.07%
1,754,465
+357,670
+26% +$4.75M
EHC icon
4
Encompass Health
EHC
$12.2B
$17.9M 5.31%
347,064
+169,582
+96% +$8.7M
ABBV icon
5
AbbVie
ABBV
$464B
$17.4M 5.15%
198,921
+136,306
+218% +$12.8M
IART icon
6
Integra LifeSciences
IART
$1.25B
$13.3M 3.93%
+281,608
New +$13.4M
IWM icon
7
PUT
iShares Russell 2000 ETF
IWM
$76.5B
$12.1M 3.57%
+80,500
New +$12.1M
CI icon
8
Cigna
CI
$74.1B
$11.4M 3.38%
67,461
+31,339
+87% +$5.52M
AHCO icon
9
AdaptHealth
AHCO
$788M
$11.3M 3.34%
518,377
+447,377
+630% +$9.39M
JNJ icon
10
Johnson & Johnson
JNJ
$644B
$11.2M 3.3%
74,979
-8,900
-11% -$1.32M
SIBN icon
11
SI-BONE Inc
SIBN
$831M
$11M 3.25%
463,150
-280,230
-38% -$5.57M
ZTS icon
12
Zoetis
ZTS
$30.2B
$7.77M 2.3%
46,960
-26,240
-36% -$4.03M
ZBH icon
13
Zimmer Biomet
ZBH
$18.5B
$7.38M 2.18%
55,861
+8,442
+18% +$1.1M
CNMD icon
14
CONMED
CNMD
$1.41B
$6.39M 1.89%
+81,205
New +$6.62M
OCUL icon
15
Ocular Therapeutix
OCUL
$2.17B
$6.37M 1.88%
837,137
+81,807
+11% +$679K
MCK icon
16
McKesson
MCK
$103B
$6.02M 1.78%
40,419
+24,477
+154% +$3.72M
SYNH
17
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$5.96M 1.76%
112,151
+57,574
+105% +$3.43M
KIDS icon
18
OrthoPediatrics
KIDS
$604M
$5.82M 1.72%
+126,764
New +$5.88M
XBI icon
19
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$5.79M 1.71%
+52,000
New +$5.83M
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
$5.29M 1.57%
372,401
-305,422
-45% -$3.05M
ESPR
21
DELISTED
Esperion Therapeutics
ESPR
$5.05M 1.49%
135,901
-47,348
-26% -$1.88M
ELV icon
22
Elevance Health
ELV
$89.5B
$4.81M 1.42%
17,909
-12,119
-40% -$3.26M
STRO icon
23
Sutro Biopharma
STRO
$259M
$4.64M 1.37%
46,217
+30,616
+196% +$2.89M
INSM icon
24
Insmed
INSM
$26.8B
$4.64M 1.37%
144,313
+4,129
+3% +$119K
MTEM
25
DELISTED
Molecular Templates, Inc.
MTEM
$4.62M 1.37%
28,186
+12,865
+84% +$2.29M
1
2 3 4

Similar funds

UVM
Upfront Ventures Management Santa Monica, California $12.3M AUM
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Endurant Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Endurant Capital Management held 82 positions worth $338M, down 81% from $1.82B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Endurant Capital Management deployed $44.3M of net new capital in Q3 2020, opening 26 new positions and adding to 20 existing holdings. Its largest new stake was Integra LifeSciences: 281,608 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 12% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Centene, an estimated $5.94M trimmed.

  • Endurant Capital Management's largest Q3 2020 buy was Integra LifeSciences: 281,608 shares worth $13.3M.
  • Endurant Capital Management added most to Bristol-Myers Squibb in Q3 2020, an estimated $21.3M increase.
  • Endurant Capital Management's biggest Q3 2020 reduction was Centene, cutting an estimated $5.94M.
  • Endurant Capital Management fully exited Medtronic in Q3 2020, selling an estimated $6.95M.
  • Endurant Capital Management's ten largest holdings make up 50% of its $338M portfolio in Q3 2020.
  • Endurant Capital Management opened 26 new positions and closed 22 in Q3 2020.
  • Endurant Capital Management's portfolio value fell 81% quarter-over-quarter to $338M.

Based on Endurant Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.